Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0YVMA)

Drug Name
IDP-123 Drug Info
Cross-matching ID
PubChem CID
5381
TTD Drug ID
D06GOF

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Antigen processing and presentation 2.26 0.00e+0 60/78 (76.92%) HLA-DQA1;CTSS;HSPA8;...
Graft-versus-host disease 2.12 0.00e+0 32/42 (76.19%) HLA-DQA1;HLA-DMB;HLA-DPB1;...
Staphylococcus aureus infection 2.10 0.00e+0 72/95 (75.79%) HLA-DQA1;KRT19;KRT18;...
Rheumatoid arthritis 1.99 2.35e-3 78/93 (83.87%) TLR4;HLA-DQA1;CCL5;...
Leishmaniasis 1.93 1.88e-3 67/77 (87.01%) TLR4;HLA-DQA1;CYBA;...
Phagosome 1.92 1.57e-3 118/152 (77.63%) TLR4;HLA-DQA1;CTSS;...
Measles 1.92 1.34e-3 133/139 (95.68%) TLR4;OAS1;CD46;...
Th1 and Th2 cell differentiation 1.90 3.52e-3 80/92 (86.96%) HLA-DQA1;LCK;HLA-DMB;...
Influenza A 1.89 4.17e-3 156/172 (90.7%) TLR4;HLA-DQA1;TNFSF10;...
Th17 cell differentiation 1.85 7.51e-3 95/107 (88.79%) HLA-DQA1;LCK;HLA-DMB;...
Allograft rejection 1.79 1.45e-2 32/38 (84.21%) HLA-DQA1;HLA-DMB;HLA-DPB1;...
Other glycan degradation 1.79 1.33e-2 13/18 (72.22%) HEXB;AGA;FUCA1;...
Pathogenic Escherichia coli infection 1.78 1.23e-2 152/197 (77.16%) TLR4;TNFSF10;F2R;...
Glycolysis / Gluconeogenesis 1.76 1.27e-2 56/67 (83.58%) FBP1;ADH5;PGAM1;...
Coronavirus disease 1.75 1.38e-2 215/232 (92.67%) TLR4;OAS1;CFD;...
NOD-like receptor signaling pathway 1.75 1.35e-2 145/181 (80.11%) TLR4;OAS1;TXNIP;...
Viral protein interaction with cytokine and cytokine re... 1.71 2.49e-2 84/100 (84%) TNFSF10;CCL5;CXCL6;...
Inflammatory bowel disease 1.71 2.35e-2 58/65 (89.23%) TLR4;HLA-DQA1;HLA-DMB;...
Lysosome 1.70 2.42e-2 115/128 (89.84%) MCOLN1;CTSS;CTSK;...
Type I diabetes mellitus 1.69 2.30e-2 38/43 (88.37%) HLA-DQA1;HLA-DMB;HLA-DPB1;...
Herpes simplex virus 1 infection 1.69 2.33e-2 165/498 (33.13%) HLA-DQA1;OAS1;CCL5;...
Amino sugar and nucleotide sugar metabolism 1.65 3.16e-2 38/48 (79.17%) HEXB;NAGK;UGP2;...
Systemic lupus erythematosus 1.64 3.06e-2 45/135 (33.33%) HLA-DQA1;C1S;HLA-DMB;...
Mismatch repair 1.64 3.05e-2 22/23 (95.65%) PCNA;RFC2;POLD4;...
Apoptosis 1.64 3.00e-2 126/168 (75%) TNFSF10;CTSS;CTSK;...
Intestinal immune network for IgA production 1.63 3.11e-2 38/48 (79.17%) HLA-DQA1;CXCL12;HLA-DMB;...
Natural killer cell mediated cytotoxicity 1.63 3.06e-2 99/131 (75.57%) TNFSF10;LCK;FCGR3B;...
Yersinia infection 1.63 2.95e-2 120/137 (87.59%) TLR4;SKAP2;LCK;...
Galactose metabolism 1.60 3.69e-2 26/31 (83.87%) UGP2;AKR1B1;GLB1;...
Mucin type O-glycan biosynthesis 1.59 3.85e-2 20/36 (55.56%) GALNT12;B4GALT5;GALNT6;...
Hypertrophic cardiomyopathy -1.71 4.80e-2 81/90 (90%) ACTC1;SGCD;DES;...
Dilated cardiomyopathy -1.71 4.58e-2 86/96 (89.58%) ACTC1;SGCD;DES;...
Vitamin digestion and absorption -1.75 3.56e-2 17/24 (70.83%) SCARB1;MMACHC;SLC19A3;...
Arginine biosynthesis -1.81 1.71e-2 17/22 (77.27%) GLUD1;ARG2;GOT1;...
ECM-receptor interaction -1.82 1.87e-2 80/88 (90.91%) AGRN;CHAD;THBS3;...
Alanine, aspartate and glutamate metabolism -1.83 2.49e-2 27/37 (72.97%) GLUD1;CAD;GOT1;...
Mineral absorption -1.97 5.34e-3 48/60 (80%) ATP2B1;SLC26A6;ATP7A;...
Protein digestion and absorption -2.03 1.07e-2 78/103 (75.73%) COL14A1;COL17A1;ATP1A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H